Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Moderate to Severe Hidradenitis Suppurativa
NCT05620823Phase 3Completed
- Sponsor
- Incyte
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 12 weeks. Started Dec 2022; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05620823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620823.